The Clinical Value of Autoantibodies in Rheumatoid Arthritis
Tóm tắt
Từ khóa
Tài liệu tham khảo
Monti, 2015, Rheumatoid arthritis treatment: the earlier the better to prevent joint damage, RMD Open, 1, e000057, 10.1136/rmdopen-2015-000057
Nam, 2017, Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis, Ann Rheum Dis, 76, 1113, 10.1136/annrheumdis-2016-210713
Bluett, 2017, Precision medicine in rheumatoid arthritis, Rheum Dis Clin North Am, 43, 377, 10.1016/j.rdc.2017.04.008
Romão, 2017, Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?, Arthritis Res Ther, 19, 239, 10.1186/s13075-017-1445-3
Malmström, 2017, The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting, Nat Rev Immunol, 17, 60, 10.1038/nri.2016.124
Derksen, 2017, The role of autoantibodies in the pathophysiology of rheumatoid arthritis, Semin Immunopathol, 39, 437, 10.1007/s00281-017-0627-z
Engelmann, 2008, IgG1 and IgG4 are the predominant subclasses among auto-antibodies against two citrullinated antigens in RA, Rheumatology, 47, 1489, 10.1093/rheumatology/ken336
Nimmerjahn, 2010, Antibody-mediated modulation of immune responses, Immunol Rev, 236, 265, 10.1111/j.1600-065X.2010.00910.x
Clavel, 2008, Induction of macrophage secretion of tumor necrosis factor alpha through Fcgamma receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen, Arthritis Rheum, 58, 678, 10.1002/art.23284
Laurent, 2011, Fcγ receptor profile of monocytes and macrophages from rheumatoid arthritis patients and their response to immune complexes formed with autoantibodies to citrullinated proteins, Ann Rheum Dis, 70, 1052, 10.1136/ard.2010.142091
Sokolove, 2014, Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis, Arthritis Rheumatol, 66, 813, 10.1002/art.38307
Laurent, 2015, IgM rheumatoid factor amplifies the inflammatory response of macrophages induced by the rheumatoid arthritis-specific immune complexes containing anticitrullinated protein antibodies, Ann Rheum Dis, 74, 1425, 10.1136/annrheumdis-2013-204543
Anquetil, 2015, IgM and IgA rheumatoid factors purified from rheumatoid arthritis sera boost the Fc receptor- and complement-dependent effector functions of the disease-specific anti-citrullinated protein autoantibodies, J Immunol, 194, 3664, 10.4049/jimmunol.1402334
Lu, 2010, Anti-citrullinated protein antibodies bind surface-expressed citrullinated Grp78 on monocyte/macrophages and stimulate tumor necrosis factor alpha production, Arthritis Rheum, 62, 1213, 10.1002/art.27386
Trouw, 2009, Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways, Arthritis Rheum, 60, 1923, 10.1002/art.24622
Okroj, 2007, Rheumatoid arthritis and the complement system, Ann Med, 39, 517, 10.1080/07853890701477546
Winchester, 1970, Gamma globulin complexes in synovial fluids of patients with rheumatoid arthritis, Clin Exp Immunol, 6, 689
Khandpur, 2013, NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis, Sci Transl Med, 5, 178, 10.1126/scitranslmed.3005580
Carmona-Rivera, 2017, Synovial fibroblast-neutrophil interactions promote pathogenic adaptive immunity in rheumatoid arthritis, Sci Immunol, 2, eaag3358, 10.1126/sciimmunol.aag3358
van, 2012, Blocking Fcα receptor I on granulocytes prevents tissue damage induced by IgA autoantibodies, J Immunol, 189, 1594, 10.4049/jimmunol.1101763
Aleyd, 2016, IgA complexes in plasma and synovial fluid of patients with rheumatoid arthritis induce neutrophil extracellular traps via FcαRI, J Immunol, 197, 4552, 10.4049/jimmunol.1502353
Teitsson, 1984, Prospective study of early rheumatoid arthritis. I. Prognostic value of IgA rheumatoid factor, Ann Rheum Dis, 43, 673, 10.1136/ard.43.5.673
Bobbio-Pallavicini, 2007, High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis, Ann Rheum Dis, 66, 302, 10.1136/ard.2006.060608
Kinslow, 2016, Elevated IgA plasmablast levels in subjects at risk of developing rheumatoid arthritis, Arthritis Rheumatol, 68, 2372, 10.1002/art.39771
Seeling, 2017, Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity?, Nat Rev Rheumatol, 13, 621, 10.1038/nrrheum.2017.146
Kaneko, 2006, Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation, Science, 313, 670, 10.1126/science.1129594
Rademacher, 1994, Agalactosyl glycoforms of IgG autoantibodies are pathogenic, Proc Natl Acad Sci USA., 91, 6123, 10.1073/pnas.91.13.6123
Tomana, 1988, Abnormal glycosylation of serum IgG from patients with chronic inflammatory diseases, Arthritis Rheum., 31, 333, 10.1002/art.1780310304
Scherer, 2010, Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid, Arthritis Rheum, 62, 1620, 10.1002/art.27414
Ercan, 2012, Hypogalactosylation of serum N-glycans fails to predict clinical response to methotrexate and TNF inhibition in rheumatoid arthritis, Arthritis Res Ther, 14, r43, 10.1186/ar3756
Gindzienska-Sieśkiewicz, 2016, Changes of glycosylation of IgG in rheumatoid arthritis patients treated with methotrexate, Adv Med Sci, 61, 193, 10.1016/j.advms.2015.12.009
Rook, 1991, Changes in IgG glycoform levels are associated with remission of arthritis during pregnancy, J Autoimmun., 4, 779, 10.1016/0896-8411(91)90173-A
Catrina, 2017, Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis, Nat Rev Rheumatol., 13, 79, 10.1038/nrrheum.2016.200
Bugatti, 2016, B cell autoimmunity and bone damage in rheumatoid arthritis, Reumatismo, 68, 117, 10.4081/reumatismo.2016.914
Grevers, 2013, Immune complex-induced inhibition of osteoclastogenesis is mediated via activating but not inhibitory Fcγ receptors on myeloid precursor cells, Ann Rheum Dis, 72, 278, 10.1136/annrheumdis-2012-201568
Seeling, 2013, Inflammatory monocytes and Fcγ receptor IV on osteoclasts are critical for bone destruction during inflammatory arthritis in mice, Proc Natl Acad Sci USA., 110, 10729, 10.1073/pnas.1301001110
Harre, 2015, Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss, Nat Commun, 6, 6651, 10.1038/ncomms7651
Harre, 2012, Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin, J Clin Invest, 122, 1791, 10.1172/JCI60975
Krishnamurthy, 2016, Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss, Ann Rheum Dis, 75, 721, 10.1136/annrheumdis-2015-208093
Hecht, 2015, Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA, Ann Rheum Dis, 74, 2151, 10.1136/annrheumdis-2014-205428
Bugatti, 2016, Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis, Arthritis Res Ther, 18, 226, 10.1186/s13075-016-1116-9
Wigerblad, 2016, Autoantibodies to citrullinated proteins induce joint pain independent of inflammation via a chemokine-dependent mechanism, Ann Rheum Dis, 75, 730, 10.1136/annrheumdis-2015-208094
van, 2017, EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis, Ann Rheum Dis, 76, 491, 10.1136/annrheumdis-2016-209846
Nielen, 2004, Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors, Arthritis Rheum, 50, 380, 10.1002/art.20018
Rantapää-Dahlqvist, 2003, Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis, Arthritis Rheum, 48, 2741, 10.1002/art.11223
Falkenburg, 2017, Evolution of autoantibody responses in individuals at risk of rheumatoid arthritis, Best Pract Res Clin Rheumatol, 31, 42, 10.1016/j.berh.2017.07.005
Rakieh, 2015, Predicting the development of clinical arthritis in anti-CCP positive individuals with non-specific musculoskeletal symptoms: a prospective observational cohort study, Ann Rheum Dis, 74, 1659, 10.1136/annrheumdis-2014-205227
van, 2011, The extent of the anti-citrullinated protein antibody repertoire is associated with arthritis development in patients with seropositive arthralgia, Ann Rheum Dis, 70, 128, 10.1136/ard.2010.132662
Bos, 2010, Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study, Ann Rheum Dis, 69, 490, 10.1136/ard.2008.105759
Withrington, 1984, Prospective study of early rheumatoid arthritis. II. Association of rheumatoid factor isotypes with fluctuations in disease activity, Ann Rheum Dis, 43, 679, 10.1136/ard.43.5.679
Robbins, 1986, Relationship of serum IgG rheumatoid factor to IgM rheumatoid factor and disease activity in rheumatoid arthritis, J Rheumatol, 13, 259
Mikuls, 2004, Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody, Arthritis Rheum, 50, 3776, 10.1002/art.20659
Bas, 2003, Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis, Rheumatology, 42, 677, 10.1093/rheumatology/keg184
van, 2005, Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis, Arthritis Res Ther, 7, R949, 10.1186/ar1767
Rönnelid, 2005, Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression, Ann Rheum Dis, 64, 1744, 10.1136/ard.2004.033571
Cader, 2010, The relationship between the presence of anti-cyclic citrullinated peptide antibodies and clinical phenotype in very early rheumatoid arthritis, BMC Musculoskelet Disord., 11, 187, 10.1186/1471-2474-11-187
Mouterde, 2014, Association of anticyclic citrullinated peptide antibodies and/or rheumatoid factor status and clinical presentation in early arthritis: results from the ESPOIR cohort, J Rheumatol, 41, 1614, 10.3899/jrheum.130884
Aletaha, 2015, Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials, Arthritis Res Ther, 17, 229, 10.1186/s13075-015-0736-9
Derksen, 2017, Rheumatoid arthritis phenotype at presentation differs depending on the number of autoantibodies present, Ann Rheum Dis, 76, 716, 10.1136/annrheumdis-2016-209794
Elliott, 2018, Affinity maturation drives epitope spreading and generation of pro-inflammatory anti-citrullinated protein antibodies in rheumatoid arthritis, Arthritis Rheumatol, 10.1002/art.40587.
López-Longo, 2009, Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis, Arthritis Rheum, 61, 419, 10.1002/art.24390
Ajeganova, 2016, Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: a longitudinal study in three European cohorts, Ann Rheum Dis, 75, 1924, 10.1136/annrheumdis-2015-208579
Ridker, 2016, From C-reactive protein to Interleukin-6 to Interleukin-1: moving upstream to identify novel targets for atheroprotection, Circ Res, 118, 145, 10.1161/CIRCRESAHA.115.306656
Majka, 2017, Association of rheumatoid factors with subclinical and clinical atherosclerosis in African American women: the multiethnic study of atherosclerosis, Arthritis Care Res, 69, 166, 10.1002/acr.22930
Cambridge, 2013, Antibodies to citrullinated peptides and risk of coronary heart disease, Atherosclerosis, 228, 243, 10.1016/j.atherosclerosis.2013.02.009
Marasovic-Krstulovic, 2011, Are the anti-cyclic citrullinated peptide antibodies independent predictors of myocardial involvement in patients with active rheumatoid arthritis?, Rheumatology, 50, 1505, 10.1093/rheumatology/ker121
Giles, 2010, Left ventricular structure and function in patients with rheumatoid arthritis, as assessed by cardiac magnetic resonance imaging, Arthritis Rheum, 62, 940, 10.1002/art.27349
Mjaavatten, 2013, Early rheumatoid arthritis: the performance of the 2010 ACR/EULAR criteria for diagnosing RA, Best Pract Res Clin Rheumatol, 27, 451, 10.1016/j.berh.2013.09.001
Nordberg, 2017, Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-naïve patients classified according to the 2010 ACR/EULAR criteria, Ann Rheum Dis, 76, 341, 10.1136/annrheumdis-2015-208873
van, 2017, What is rheumatoid arthritis? Considering consequences of changed classification criteria, Ann Rheum Dis, 76, 315, 10.1136/annrheumdis-2016-209629
Boer, 2018, Is anti-citrullinated protein antibody-positive rheumatoid arthritis still a more severe disease than anti-citrullinated protein antibody-negative rheumatoid arthritis? A longitudinal cohort study in rheumatoid arthritis patients diagnosed from 2000 onward, Arthritis Care Res, 70, 987, 10.1002/acr.23497
Barra, 2017, The effect of rheumatoid arthritis-associated autoantibodies on the incidence of cardiovascular events in a large inception cohort of early inflammatory arthritis, Rheumatology, 56, 768, 10.1093/rheumatology/kew474
Smolen, 2017, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update, Ann Rheum Dis, 76, 960, 10.1136/annrheumdis-2016-210715
Ajeganova, 2017, Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations, Ther Adv Muscuoloskelet Dis, 9, 249, 10.1177/1759720X17720366
Bugatti, 2018, Clinical, imaging, and pathological suppression of synovitis in rheumatoid arthritis: is the disease curable?, Front Med, 5, 140, 10.3389/fmed.2018.00140
Verstappen, 2005, A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up, Ann Rheum Dis, 64, 38, 10.1136/ard.2003.014928
Pease, 1999, Does the age at onset of rheumatoid arthritis influence phenotype?: a prospective study of outcome and prognostic factors, Rheumatology, 38, 228, 10.1093/rheumatology/38.3.228
Forslind, 2007, Sex: a major predictor of remission in early rheumatoid arthritis?, Ann Rheum Dis, 66, 46, 10.1136/ard.2006.056937
Bluett, 2018, Risk factors for oral methotrexate failure in patients with inflammatory polyarthritis: results from a UK prospective cohort study, Arthritis Res Ther, 20, 50, 10.1186/s13075-018-1544-9
Wevers-de, 2012, Remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study), Ann Rheum Dis, 71, 1472, 10.1136/annrheumdis-2011-200736
De, 2018, Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes, Arthritis Res Ther, 20, 33, 10.1186/s13075-018-1520-4
Raheek, 2017, Improved flare and remission pattern in rheumatoid arthritis over recent decades: a population-based study, Rheumatology, 56, 2154, 10.1093/rheumatology/kex352
Wevers-de, 2015, Determinants of reaching drug-free remission in patients with early rheumatoid or undifferentiated arthritis after one year of remission-steered treatment, Rheumatology, 54, 1380, 10.1093/rheumatology/keu477
Paulshus, 2018, Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol, Rheumatology, 57, 2022, 10.1093/rheumatology/key202
Van, 2009, Prevalence and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts, Arthritis Rheum, 60, 2262, 10.1002/art.24661
Klarenbeek, 2011, Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study, Ann Rheum Dis, 70, 315, 10.1136/ard.2010.136556
Haschka, 2016, Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomized controlled RETRO study, Ann Rheum Dis, 75, 45, 10.1136/annrheumdis-2014-206439
Rech, 2016, Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment, Ann Rheum Dis, 75, 1637, 10.1136/annrheumdis-2015-207900
Figueiredo, 2017, Antimodified protein antibody response pattern influences the risk of disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs, Ann Rheum Dis, 76, 399, 10.1136/annrheumdis-2016-209297
Schett, 2016, Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions, Ann Rheum Dis, 75, 1428, 10.1136/annrheumdis-2016-209201
Singh, 2016, 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis, Arthritis Rheumatol, 68, 1, 10.1002/art.39480
van, 2012, The association of treatment response and joint damage with ACPA-status in recent-onset RA: a subanalysis of the 8-year follow-up of the BeSt study, Ann Rheum Dis, 71, 245, 10.1136/annrheumdis-2011-200379
Dekkers, 2018, Autoantibody status is not associated with early treatment response to first-line methotrexate in patients with early rheumatoid arthritis, Rheumatology, 10.1093/rheumatology/key263
Jonsson, 2018, The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy, Arthritis Res Ther, 20, 146, 10.1186/s13075-018-1635-7
van, 2007, Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial, Arthritis Rheum, 56, 1424, 10.1002/art.22525
Crepaldi, 2017, The 2010 classification criteria and a more aggressive treatment strategy improve clinical outcomes in seropositive but not seronegative rheumatoid arthritis, Ann Rheum Dis, 76, 237, 10.1136/annrheumdis-2017-eular.5101
Seegobin, 2014, ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial, Arthritis Res Ther, 16, r13, 10.1186/ar4439
Brown, 2016, Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers, Nat Rev Rheumatol, 12, 731, 10.1038/nrrheum.2016.175
Isaacs, 2013, Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis, Ann Rheum Dis, 72, 329, 10.1136/annrheumdis-2011-201117
Maneiro, 2013, Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis, Semin Arthritis Rheum, 43, 9, 10.1016/j.semarthrit.2012.11.007
Sokolove, 2016, Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial, Ann Rheum Dis, 75, 709, 10.1136/annrheumdis-2015-207942
Gottenberg, 2012, Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry, Ann Rheum Dis, 71, 1815, 10.1136/annrheumdis-2011-201109
Gottenberg, 2016, Brief report: association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of abatacept: results from the Pan-European registry analysis, Arthritis Rheumatol., 68, 1346, 10.1002/art.39595
Nüßlein, 2016, Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study, Clin Exp Rheumatol, 34, 489
Alten, 2017, Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study, RMD Open, 3, e000345, 10.1136/rmdopen-2016-000345
Wunderlich, 2017, Effects of DMARDs on citrullinated peptide autoantibody levels in RA patients-A longitudinal analysis, Semin Arthritis Rheum, 46, 709, 10.1016/j.semarthrit.2016.09.011
Jansen, 2018, Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study, RMD Open, 4, e000564, 10.1136/rmdopen-2017-000564
Lv, 2014, The status of rheumatoid factor and anti-citrullinated peptide antibody are not associated with the effect of anti-TNFα agent treatment in patients with rheumatoid arthritis: a meta-analysis, PLoS ONE, 9, e89442, 10.1371/journal.pone.0089442
De, 2005, Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis, Ann Rheum Dis, 64, 299, 10.1136/ard.2004.023523
Takeuchi, 2011, Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis, Ann Rheum Dis, 70, 1208, 10.1136/ard.2011.153023
Takeuchi, 2017, High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study, Arthritis Res Ther, 19, 194, 10.1186/s13075-017-1401-2
Kawashiri, 2011, Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index, Mod Rheumatol, 21, 365, 10.3109/s10165-010-0402-7
Pers, 2014, Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice, Rheumatology, 53, 76, 10.1093/rheumatology/ket301
Ducreux, 2014, Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium, Arthritis Rheumatol, 66, 15, 10.1002/art.38202